WAYRILZ offers long-lasting platelet control and was studied for impact on patient-reported quality of life.
Long-lasting platelet control
WAYRILZ improves and sustains platelet counts.
- During the last 12 weeks of the study, 23% of people taking WAYRILZ (vs 0% of those who did not) reached a platelet level of 50,000 or higher more than 5 times when measured weekly, without rescue therapy, including at least twice in the final 6 weeks.*
Designed to target key sources of ITP
WAYRILZ works in multiple ways to protect platelets and help restore immune balance.
An established safety profile in the clinical study
The most common side effects included diarrhea, nausea, headache, abdominal pain, and COVID-19.
*The clinical study focused on adults with persistent or chronic ITP who didn’t respond well to or couldn’t tolerate previous treatments. It compared 133 people who took WAYRILZ to 69 people who did not for a total of 24 weeks (or 6 months).
Interested in learning more?
Sign up to receive more information about WAYRILZ and to connect with a Sanofi Clinical Educator.
Sanofi Patient Support from HemAssist™
HemAssist supports you with WAYRILZ treatment access, financial assistance, and education throughout your treatment journey.
Call us at 1-833-723-5463 Monday – Friday 8 AM to 7 PM ET
WAYRILZ is a prescription medicine that is used to treat adults with persistent or chronic immune thrombocytopenia (ITP) who received a prior treatment that did not work well enough.
It is not known if WAYRILZ is safe and effective in children.
What should I tell my healthcare provider before taking WAYRILZ?
Tell your healthcare provider about all of your medical conditions, including if you:
- have liver problems
- have kidney problems
- are pregnant or plan to become pregnant. WAYRILZ may harm your unborn baby. If you are able to have a baby, your healthcare provider will do a pregnancy test before starting treatment with WAYRILZ. Females who are able to become pregnant should use an effective birth control during treatment with WAYRILZ and for 1 week after the last dose.
- are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with WAYRILZ and for at least 1 week after the last dose.
Tell your healthcare provider about all the medicines you take, including prescription and over‑the‑counter medicines, vitamins, and herbal supplements. Taking WAYRILZ with certain other medicines may affect how WAYRILZ works and can cause side effects. WAYRILZ may also affect how other medicines work.
What should I avoid while taking WAYRILZ?
You should avoid grapefruit, starfruit and products that have these fruits, and Seville oranges (often used in marmalades) during treatment with WAYRILZ. These products may increase the amount of WAYRILZ in your blood, which increases the risk of side effects of WAYRILZ.
What are the possible side effects of WAYRILZ?
WAYRILZ may cause serious side effects, including:
- Serious infections. WAYRILZ can increase the risk of infections, including serious infections that can lead to death. Your healthcare provider will check you for signs and symptoms of infection during your treatment with WAYRILZ. Tell your healthcare provider right away if you get any signs or symptoms of infection, including fever, chills, or flu-like symptoms.
- Liver problems including Drug-Induced Liver Injury (DILI). Liver problems, which may be severe, life-threatening, or lead to death have happened in people treated with Bruton’s tyrosine kinase (BTK) inhibitors. Your healthcare provider will do blood tests to check your liver before and as necessary during treatment with WAYRILZ. Tell your healthcare provider right away if you have any signs or symptoms of liver problems, including stomach-area (abdominal) pain or discomfort, dark or “tea-colored” urine, or yellowing of the skin or the white part of your eyes.
The most common side effects of WAYRILZ include diarrhea, nausea, headache, stomach area (abdominal) pain, and COVID-19.
These are not all of the possible side effects of WAYRILZ.
Please see full Prescribing Information, including Patient Information.
